 Multiple Myeloma
"Multiple Myeloma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
| Descriptor ID |
D009101
|
| MeSH Number(s) |
C04.557.595.500 C14.907.454.460 C15.378.147.780.650 C15.378.463.515.460 C20.683.515.845 C20.683.780.650
|
| Concept/Terms |
Multiple Myeloma- Multiple Myeloma
- Multiple Myelomas
- Myeloma, Multiple
- Myelomas, Multiple
- Myeloma-Multiple
- Myeloma Multiple
- Myeloma-Multiples
- Plasma Cell Myeloma
- Cell Myeloma, Plasma
- Cell Myelomas, Plasma
- Myelomas, Plasma Cell
- Plasma Cell Myelomas
- Kahler Disease
- Disease, Kahler
- Myeloma, Plasma-Cell
- Myeloma, Plasma Cell
- Myelomas, Plasma-Cell
- Plasma-Cell Myeloma
- Plasma-Cell Myelomas
- Myelomatosis
- Myelomatoses
|
Below are MeSH descriptors whose meaning is more general than "Multiple Myeloma".
Below are MeSH descriptors whose meaning is more specific than "Multiple Myeloma".
This graph shows the total number of publications written about "Multiple Myeloma" by people in this website by year, and whether "Multiple Myeloma" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1981 | 0 | 4 | 4 | | 1982 | 0 | 1 | 1 | | 1983 | 1 | 1 | 2 | | 1986 | 0 | 1 | 1 | | 1987 | 0 | 2 | 2 | | 1989 | 2 | 0 | 2 | | 1991 | 0 | 1 | 1 | | 1992 | 1 | 1 | 2 | | 1993 | 1 | 0 | 1 | | 1995 | 1 | 0 | 1 | | 1996 | 0 | 1 | 1 | | 1997 | 1 | 0 | 1 | | 1998 | 2 | 1 | 3 | | 1999 | 2 | 1 | 3 | | 2000 | 1 | 2 | 3 | | 2001 | 2 | 0 | 2 | | 2002 | 3 | 0 | 3 | | 2003 | 0 | 1 | 1 | | 2004 | 3 | 0 | 3 | | 2005 | 2 | 2 | 4 | | 2006 | 3 | 1 | 4 | | 2007 | 2 | 1 | 3 | | 2008 | 4 | 0 | 4 | | 2009 | 5 | 3 | 8 | | 2010 | 4 | 4 | 8 | | 2011 | 10 | 2 | 12 | | 2012 | 13 | 0 | 13 | | 2013 | 7 | 0 | 7 | | 2014 | 10 | 2 | 12 | | 2015 | 9 | 0 | 9 | | 2016 | 11 | 0 | 11 | | 2017 | 16 | 2 | 18 | | 2018 | 10 | 1 | 11 | | 2019 | 13 | 0 | 13 | | 2020 | 3 | 0 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Multiple Myeloma" by people in Profiles.
-
Nabulsi NA, Alobaidi A, Talon B, Asfaw AA, Zhou J, Sharp LK, Sweiss K, Patel PR, Ko NY, Chiu BC, Calip GS. Self-reported health and survival in older patients diagnosed with multiple myeloma. Cancer Causes Control. 2020 Jul; 31(7):641-650.
-
Gavriatopoulou M, Chari A, Chen C, Bahlis N, Vogl DT, Jakubowiak A, Dingli D, Cornell RF, Hofmeister CC, Siegel D, Berdeja JG, Reece D, White D, Lentzsch S, Gasparetto C, Huff CA, Jagannath S, Baz R, Nooka AK, Richter J, Abonour R, Parker TL, Yee AJ, Moreau P, Lonial S, Tuchman S, Weisel KC, Mohty M, Choquet S, Unger TJ, Li K, Chai Y, Li L, Shah J, Shacham S, Kauffman MG, Dimopoulos MA. Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. Leukemia. 2020 09; 34(9):2430-2440.
-
Dimopoulos MA, Jakubowiak AJ, McCarthy PL, Orlowski RZ, Attal M, Bladé J, Goldschmidt H, Weisel KC, Ramasamy K, Zweegman S, Spencer A, Huang JSY, Lu J, Sunami K, Iida S, Chng WJ, Holstein SA, Rocci A, Skacel T, Labotka R, Palumbo A, Anderson KC. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. Blood Cancer J. 2020 02 13; 10(2):17.
-
Alobaidi A, Nabulsi NA, Talon B, Asfaw AA, Zhou J, Sharp LK, Sweiss K, Patel PR, Ko NY, Chiu BC, Calip GS. Depressive symptoms, mental health-related quality of life, and survival among older patients with multiple myeloma. Support Care Cancer. 2020 Sep; 28(9):4097-4106.
-
Sridharan A, Schinke CD, Georgiev G, Da Silva Ferreira M, Thiruthuvanathan V, MacArthur I, Bhagat TD, Choudhary GS, Aluri S, Chen J, Pradhan K, Xia Y, Panjikaran M, Sims G, Bhagat CK, Bender R, Keeler L, Graber A, Heuck C, Fletcher FA, Alapat D, Weinhold N, Johnson SK, Wickrema A, Barlogie B, Morgan GJ, Shastri A, Steidl U, Will B, Verma A. Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias. Blood Adv. 2019 12 10; 3(23):3962-3967.
-
Mateos MV, Cavo M, Blade J, Dimopoulos MA, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Krevvata M, Chen Y, Wang J, Kudva A, Ukropec J, Wroblewski S, Qi M, Kobos R, San-Miguel J. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet. 2020 01 11; 395(10218):132-141.
-
Hari P, Matous JV, Voorhees PM, Shain KH, Obreja M, Frye J, Fujii H, Jakubowiak AJ, Rossi D, Sonneveld P. Oprozomib in patients with newly diagnosed multiple myeloma. Blood Cancer J. 2019 08 16; 9(9):66.
-
Ugai T, Ito H, Oze I, Saito E, Rahman MS, Boffetta P, Gupta PC, Sawada N, Tamakoshi A, Shu XO, Koh WP, Gao YT, Sadakane A, Tsuji I, Park SK, Nagata C, You SL, Pednekar MS, Tsugane S, Cai H, Yuan JM, Xiang YB, Ozasa K, Tomata Y, Kanemura S, Sugawara Y, Wada K, Chen CJ, Yoo KY, Chia KS, Ahsan H, Zheng W, Inoue M, Kang D, Potter J, Matsuo K. Association of BMI, Smoking, and Alcohol with Multiple Myeloma Mortality in Asians: A Pooled Analysis of More than 800,000 Participants in the Asia Cohort Consortium. Cancer Epidemiol Biomarkers Prev. 2019 11; 28(11):1861-1867.
-
Landgren O, Sonneveld P, Jakubowiak A, Mohty M, Iskander KS, Mezzi K, Siegel DS. Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma. Leukemia. 2019 09; 33(9):2127-2143.
-
Pianko MJ, Devlin SM, Littmann ER, Chansakul A, Mastey D, Salcedo M, Fontana E, Ling L, Tavitian E, Slingerland JB, Slingerland AE, Clurman A, Gomes ALC, Taur Y, Pamer EG, Peled JU, van den Brink MRM, Landgren O, Lesokhin AM. Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition. Blood Adv. 2019 07 09; 3(13):2040-2044.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|